A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
מצבים רפואיים
PROC · Platinum Resistant Ovarian Cancer · Endometrial Cancer
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
University of Arkansas - Winthrop P. Rockefeller Cancer Institute, Little Rock, Arkansas, United States
START - Los Angeles, Los Angeles, California, United States
SCRI - Florida Cancer Specialists, Sarasota, Florida, United States
St. Francis Medical Center (OSF Healthcare), Peoria, Illinois, United States
Contact: Study coordinator (Michelle Rowland, MD) · michelle.rowland@osfhealthcare.org · 309-308-3350Karmanos Cancer Center, Detroit, Michigan, United States
Start - Ny, Lake Success, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Atrium Health - Wake Forest, Charlotte, North Carolina, United States
Contact: Study coordinator (Michelle Treadwell) · michelle.treadwell@advocatehealth.org · 980-442-2000Ohio State University Wexner Medical Center, Columbus, Ohio, United States
SCRI - Sydney Kimmel Cancer Center - Jefferson Health, Philadelphia, Pennsylvania, United States
SCRI - Mary Crowley Cancer Research, Dallas, Texas, United States
START Mountain, Salt Lake City, Utah, United States
מובילי המחקר
Margaret C Dugan, MD
Study Director
Whitehawk Therapeutics
Edward Spindler, BS, MBA
Study Director
Whitehawk Therapeutics